Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dividend investing for retirement -- Ignore unavailable to you. Want to Upgrade?

To: Max Fletcher who wrote (974)	1/18/2008 5:38:35 PM
From: Steve Felix	Respond to of 34328

This guy does seem like a fool. gg From the Fool: Then again, I told you we'd get nasty. These 17 stocks have warts, and we're going to point them out, even if it hurts. You can vote here. I think I'll just watch. fool.com Here is the guys take on Pfe: ____________________________________________________________ Worst Stock for 2008: Pfizer By Brian Lawler January 14, 2008 I cringe as I anoint Pfizer (NYSE: PFE), which has done such good work for humanity, as a "worst stock," so I'll preface everything I say by noting that a "worst stock" is not anything close to meaning worst company, at least in the pharma and biotech sectors. The worst drugmaker distinction would go to Neurochem (Nasdaq: NRMX) or Telik (Nasdaq: TELK) -- both one-star CAPS stocks, by the way. Even though the pharmaceutical and biotech sectors are some of the best sectors for investors to be in during a recession (and we are in one, even if the economic data hasn't caught up yet), Pfizer has to be tagged with the "worst stock" label because it's the least appetizing of the big pharmas for several reasons. I'm not going to spend much time discussing the upcoming turn-of-the-decade event for Pfizer's lead drug, Lipitor. That's been done ad nauseam. It's worth pointing out, though, for those expecting a few more strong years for Lipitor, that the drug's sales erosion is already under way because of increasing competition from other generic and branded statins. Sales of the cholesterol-lowering drug fell 5% year over year in the third quarter last year. Five percent may not sound like much, but that translates into hundreds of millions of dollars in reduced sales annually. Any analyst could point to the decline or failure of individual drugs with a large pharma such as Pfizer, Merck (NYSE: MRK), or GlaxoSmithKline (NYSE: GSK) and paint a picture that makes the company's future look prettier or uglier than it really is. The more important theme, though, is that Pfizer's pipeline is extremely weak in regard to new molecular entities, and most of its phase 3 drug candidates are label expansions of already approved compounds. A drugmaker primarily focused on biologics can get away with a late-stage pipeline consisting mostly of label expansions, like Genentech (NYSE: DNA) and the several million studies it's testing Avastin in, because it doesn't have to worry as much about generic competitors. Unfortunately, Pfizer is not such a drugmaker and needs new molecules on the market to compensate for its marketed drugs facing patent expiration. And that's the rub with Pfizer; the level of pipeline innovation that it needs to continuously generate new growth for its top line is unprecedented. Pfizer isn't a badly run drugmaker. Rather, it's suffering from the inevitable and enviable consequences of developing many of the world's best-selling drugs and then having to watch generic compounds take their place. Unlike other Fools, I see Pfizer as more of a value trap than a value play. "Cigar-butt stocks," as Ben Graham calls them, and stocks with declining top-line sales can definitely make excellent investment opportunities at the right price, but in the words of the famous analyst Happy Gilmore, "the price is wrong" right now with Pfizer. Guidance from Pfizer is for another year of flat to declining sales, with operating cash flow up only marginally from its 2006 levels. I don't know about you, but I usually prefer a little growth in my stocks, even if Pfizer could afford to bulk up the dividend another 50% right now, given the amount of free cash flow it's generating (that won't be possible four years from now). I'm not sure what the sound of billions of dollars of drugs going off patent sounds like, but from now until the end of 2012, we'll get to find out as Pfizer loses patent protection on many of its top drugs, including Viagra and Lipitor. With so many other pharmas out there with fewer problems and better growth prospects such as Gilead Sciences (Nasdaq: GILD), even a 5% dividend yield isn't enough to get me excited about Pfizer. If you agree that Pfizer's chances of making it big in 2008 are as good as Wayne Gretzky making it on the PGA tour, join me in marking Pfizer as an underperform in CAPS. Then come back next week, and we'll let you know who you picked as the worst stock for 2008.

To: Max Fletcher who wrote (974)	2/9/2008 5:43:05 PM
From: Steve Felix	Read Replies (2) \| Respond to of 34328

Curious how you like the Fool letter Max. I won't be renewing Morningstar Dividend Investor. I'm glad I haven't followed him into some of his picks. <Josh Peters has MMA as a one fisted table pounding buy. 14.4% yield. Do your own dd.> Message 24170480 As of that day MMA closed at $14.73, down 50% for the year. Now known as [t]MMAB.pk[/t], it closed at $6.47 Friday. Why pay someone to get blindsided like this: BALTIMORE--(BUSINESS WIRE)--Jan. 28, 2008--Municipal Mortgage & Equity, LLC ("MuniMae" or "the Company," NYSE: MMA) announced today that its Board of Directors has declared a dividend distribution of $0.33 per common share payable on February 15, 2008 to shareholders of record as of February 5, 2008. The Company also announced that while it expects to have completed by the end of February, its substantive work required to prepare its 2006 financial statements and its restated audited financial statements for 2005 and 2004, the Company does not expect to be able to file its audited financial statements by its previously announced goal of March 3, 2008. Based on work done to date, the Company does not believe the results of the restatement will materially change the previously recorded cash balances of the Company and its subsidiaries. The reduction in the dividend distribution from $0.5250 to $0.33 per share is due to the cost of the Company's ongoing restatement of its financial statements, the decision by the Company to conserve capital to protect the long-term prospects of the business given the current volatility in the credit and capital markets, and the desire to dedicate additional capital to the high-growth Renewable Energy Finance business, an increasingly important part of the Company's business. A portion of this dividend will be paid from sources other than cash generated from operations. The Board of Directors will continue to review the Company's dividend payout on a quarterly basis based, among other factors, on the Company's net cash generation and the strategic needs of the business. phx.corporate-ir.net